[go: up one dir, main page]

UY35078A - Modulación de la expresión de receptores androgénicos - Google Patents

Modulación de la expresión de receptores androgénicos

Info

Publication number
UY35078A
UY35078A UY0001035078A UY35078A UY35078A UY 35078 A UY35078 A UY 35078A UY 0001035078 A UY0001035078 A UY 0001035078A UY 35078 A UY35078 A UY 35078A UY 35078 A UY35078 A UY 35078A
Authority
UY
Uruguay
Prior art keywords
androgenic
receivers
modulation
expression
proliferation
Prior art date
Application number
UY0001035078A
Other languages
English (en)
Inventor
Robert A Macleod
Kim Youngsoo
Zhou Tianyuan
Susan M Freier
Seth Punit
Swayze Eric
Monia Brett
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50475891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY35078(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of UY35078A publication Critical patent/UY35078A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)

Abstract

Ciertas realizaciones se refieren a compuestos y composiciones que tienen como diana un receptor androgénico (RA) humano para inhibir los niveles del receptor androgénico en una célula, lo cual puede resultar útil en métodos de tratamiento del cáncer y de inhibición del crecimiento o la proliferación de células cancerosas.
UY0001035078A 2012-10-11 2013-10-11 Modulación de la expresión de receptores androgénicos UY35078A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261712780P 2012-10-11 2012-10-11
US201261712756P 2012-10-11 2012-10-11
US201261723701P 2012-11-07 2012-11-07
US201361777851P 2013-03-12 2013-03-12
US201361777813P 2013-03-12 2013-03-12
US201361777895P 2013-03-12 2013-03-12

Publications (1)

Publication Number Publication Date
UY35078A true UY35078A (es) 2014-03-31

Family

ID=50475891

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035078A UY35078A (es) 2012-10-11 2013-10-11 Modulación de la expresión de receptores androgénicos

Country Status (31)

Country Link
US (3) US9175291B2 (es)
EP (1) EP2906226B1 (es)
JP (2) JP6306598B2 (es)
KR (1) KR102124228B1 (es)
CN (2) CN108300718B (es)
AP (1) AP2015008368A0 (es)
AR (1) AR092982A1 (es)
AU (2) AU2013329070A1 (es)
BR (1) BR112015007878A2 (es)
CA (1) CA2887867C (es)
CL (1) CL2015000901A1 (es)
CO (1) CO7400882A2 (es)
DK (1) DK2906226T3 (es)
DO (1) DOP2015000083A (es)
EC (1) ECSP15012462A (es)
ES (1) ES2706387T3 (es)
IL (2) IL237855A0 (es)
MX (1) MX369207B (es)
NI (1) NI201500051A (es)
NZ (1) NZ706151A (es)
PE (1) PE20150722A1 (es)
PH (1) PH12015500788A1 (es)
PL (1) PL2906226T3 (es)
PT (1) PT2906226T (es)
RU (1) RU2670486C9 (es)
SG (1) SG11201502505UA (es)
TN (1) TN2015000140A1 (es)
TW (1) TW201420594A (es)
UY (1) UY35078A (es)
WO (1) WO2014059238A2 (es)
ZA (1) ZA201503203B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2739153T3 (en) 2011-07-29 2018-12-03 Medivation Prostate Therapeutics Llc TREATMENT OF BREAST CANCER
MX362555B (es) 2012-03-05 2019-01-24 Oy Arctic Partners Ab Metodos y aparatos para predecir riesgo de cancer de prostata y volumen de glandula prostatica.
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
DE202015009668U1 (de) 2014-03-28 2019-01-21 Opko Diagnostics, Llc Zusammensetzungen zur Diagnose von Prostatakrebs
AU2015360767A1 (en) 2014-12-12 2017-06-08 Medivation Prostate Therapeutics Llc Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
WO2016138353A1 (en) 2015-02-26 2016-09-01 Ionis Pharmaceuticals, Inc. Allele specific modulators of p23h rhodopsin
PT3253800T (pt) 2015-03-27 2021-04-28 Opko Diagnostics Llc Padrões de antigénio da próstata e suas utilizações
EP3824908A1 (en) 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
CN105492632B (zh) * 2015-07-01 2021-08-06 深圳市第二人民医院 一种检测与特发性无精子症相关的遗传标记的引物对
WO2017053999A1 (en) * 2015-09-25 2017-03-30 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
US10682362B2 (en) * 2015-10-14 2020-06-16 Wayne State University Treatments and diagnostics for cancers
CN105541991B (zh) * 2015-12-16 2019-05-31 中国医科大学 Bap18在促进前列腺癌方面的应用
WO2017123996A1 (en) * 2016-01-15 2017-07-20 City Of Hope Targeting glioblastoma stem cells through the tlx-tet3 axis
EP3417064A4 (en) * 2016-02-18 2019-10-23 Ionis Pharmaceuticals, Inc. KLK3 ACTIVATOR RNA MODULATORS
EP3464623B1 (en) * 2016-06-02 2021-09-01 Sint-Augustinus Androgen receptor splice variants and androgen deprivation therapy
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
US10933134B2 (en) * 2017-03-16 2021-03-02 Memorial Sloan Kettering Cancer Center Combination therapies for treatment of cancer
AU2019218987B2 (en) 2018-02-12 2025-04-24 Ionis Pharmaceuticals, Inc. Modified compounds and uses thereof
US11866689B2 (en) 2018-03-26 2024-01-09 Duke University Splice-switching oligonucleotides and methods of use
CN109321569B (zh) * 2018-10-29 2022-04-12 迈杰转化医学研究(苏州)有限公司 一种引物探针组合物及其应用
TW202028222A (zh) * 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
US20220002723A1 (en) * 2018-11-14 2022-01-06 Board Of Regents, The University Of Texas System Methods for the treatment of small round cell tumors
KR102473989B1 (ko) 2018-11-28 2022-12-07 (주)바이오니아 안드로젠 수용체 특이적 서열을 포함하는 이중나선 올리고뉴클레오티드 구조체, 및 이를 포함하는 탈모 예방 및 발모용 조성물
WO2020148400A1 (en) * 2019-01-16 2020-07-23 Stichting Katholieke Universiteit Antisense oligonucleotides for use in the treatment of crpc
CN109880931A (zh) * 2019-04-11 2019-06-14 江苏省农业科学院 一种丝瓜抗黄瓜花叶病毒cmv主效qtl的slaf-snp分子标记方法及应用
US20220323444A1 (en) * 2019-07-29 2022-10-13 The Medical College Of Wisconsin, Inc. Methods of Treating Advanced Prostate Cancer
EP3791930A1 (en) * 2019-09-13 2021-03-17 Secarna Pharmaceuticals GmbH & Co. KG Inhibitor of metadherin expression
JP2023501352A (ja) * 2019-11-08 2023-01-18 アイオーニス ファーマシューティカルズ， インコーポレーテッド Ｓｐｄｅｆ発現を低減するための化合物及び方法
CN116370491A (zh) * 2021-09-22 2023-07-04 北京瑞博开拓医药科技有限公司 反义寡核苷酸剂在治疗冠状病毒相关疾病中的应用
CN116270710B (zh) * 2023-02-16 2025-01-28 南方医科大学珠江医院 circRBM33作为靶点在前列腺癌诊断和治疗中的应用
WO2024220955A2 (en) * 2023-04-21 2024-10-24 Memorial Sloan Kettering Cancer Center Combining induction of ferroptosis with targeted agents for cancer therapy
CN121065176A (zh) * 2025-04-14 2025-12-05 羿美诚健(上海)生物医药有限公司 靶向雄激素受体的小核酸及其药物组合物和用途

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2699808A (en) 1944-10-06 1955-01-18 Mark W Lowe Apparatus for peeling tomatoes
US2699508A (en) 1951-12-21 1955-01-11 Selectronics Inc Method of mounting and construction of mounting for low frequency piezoelectric crystals
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
FR2567892B1 (fr) 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
DE69034150T2 (de) 1989-10-24 2005-08-25 Isis Pharmaceuticals, Inc., Carlsbad 2'-Modifizierte Oligonukleotide
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
DK0455905T3 (da) 1990-05-11 1998-12-07 Microprobe Corp Dipsticks til nukleinsyrehybridiseringsassays og fremgangsmåde til kovalent immobilisering af oligonukleotider
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US5877160A (en) 1991-05-31 1999-03-02 Genta Incorporated Compositions and methods of treatment of androgen-associated baldness using antisense oligomers
US7517644B1 (en) 1991-08-23 2009-04-14 Larry J. Smith Method and compositions for cellular reprogramming
EP0538194B1 (de) 1991-10-17 1997-06-04 Novartis AG Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
FR2687679B1 (fr) 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
EP0577558A2 (de) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
JPH08504559A (ja) 1992-12-14 1996-05-14 ハネウエル・インコーポレーテッド 個別に制御される冗長巻線を有するモータシステム
WO1994018835A1 (en) 1993-02-19 1994-09-01 Genta Incorporated Treatment of androgen-associated baldness using antisense oligomers
ES2107205T3 (es) 1993-03-30 1997-11-16 Sanofi Sa Analogos de nucleosidos aciclicos y secuencias oligonucleotidas que los contienen.
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5556956A (en) 1993-11-04 1996-09-17 Board Of Regents, The University Of Texas System Methods and compositions relating to the androgen receptor gene and uses thereof
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
EP0851919A1 (en) 1995-09-20 1998-07-08 University of Massachusetts Worcester Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate
US6300060B1 (en) 1995-11-09 2001-10-09 Dana-Farber Cancer Institute, Inc. Method for predicting the risk of prostate cancer morbidity and mortality
US5656408A (en) 1996-04-29 1997-08-12 Xerox Corporation Coated carrier particles
US6489163B1 (en) 1996-05-08 2002-12-03 Board Of Regents, The University Of Texas System Ribozyme mediated inactivation of the androgen receptor
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
US5994076A (en) 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
AU9063398A (en) 1997-09-12 1999-04-05 Exiqon A/S Oligonucleotide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US20030228597A1 (en) 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
US6043352A (en) 1998-08-07 2000-03-28 Isis Pharmaceuticals, Inc. 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
AU5723199A (en) 1998-09-15 2000-04-03 Signalgene Inc. Marker at the androgen receptor gene for determining breast cancer susceptibility
KR20010112944A (ko) 1999-04-21 2001-12-22 이곤 이 버그 폴리뉴클레오티드 서열의 기능을 억제하기 위한 방법 및조성물
AU776362B2 (en) 1999-05-04 2004-09-09 Roche Innovation Center Copenhagen A/S L-ribo-LNA analogues
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
AU2698301A (en) 1999-12-30 2001-07-16 K.U. Leuven Research And Development Cyclohexene nucleic acids
US6255110B1 (en) 2000-01-21 2001-07-03 Isis Pharmaceuticals, Inc. Antisense modulation of ARA70 expression
AU2001244004A1 (en) 2000-03-28 2001-10-08 Signalgene Inc. Method for determining osteoporosis susceptibility and/or low bone density and reagents therefor
WO2001077384A2 (de) 2000-04-07 2001-10-18 Epigenomics Ag DETEKTION VON SNPs UND CYTOSIN-METHYLIERUNGEN
AU5752601A (en) 2000-05-04 2001-11-12 Avi Biopharma Inc Splice-region antisense composition and method
RU2003102390A (ru) * 2000-06-28 2004-05-27 Бристол-Маерс Сквибб Компани (Us) Селективные модуляторы рецептора андрогена и способы их идентификации, изготовления и применения
JP2004517606A (ja) 2000-06-28 2004-06-17 ブリストル−マイヤーズ　スクイブ　カンパニー アンドロゲンレセプターモデュレーターの同定のための細胞株および細胞ベースのアッセイ
IL152719A0 (en) 2000-06-28 2003-06-24 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification
WO2002010452A2 (en) 2000-07-27 2002-02-07 University Of Rochester Methods and compositions for predicting prostate cancer
US20020165381A1 (en) 2000-11-30 2002-11-07 Isabelle Ahrens-Fath Human androgen receptor variants
JP2002247986A (ja) 2001-02-23 2002-09-03 Mitsui Chemicals Inc 性ホルモン受容体作用評価に有用な細胞
WO2002085308A2 (en) 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
US20050159376A1 (en) 2002-02-20 2005-07-21 Slrna Therapeutics, Inc. RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
EP1499627A2 (en) 2001-07-03 2005-01-26 ISIS Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
US6680342B2 (en) 2001-09-20 2004-01-20 Mayo Foundation For Medical Education And Research Methods and compositions for inhibiting the proliferation of prostate cancer cells
FR2832154B1 (fr) 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
JP2004008140A (ja) 2002-06-10 2004-01-15 Sumitomo Chem Co Ltd 変異型アンドロゲンレセプターおよびその活性評価用細胞
WO2004011624A2 (en) 2002-07-31 2004-02-05 Nucleonics, Inc. Double stranded rna structures and constructs, and methods for generating and using the same
WO2004035765A2 (en) 2002-10-18 2004-04-29 Nucleonics, Inc. Double-stranded rna structures and constructs, and methods for generating and using the same
EP1581217A4 (en) 2002-11-01 2007-07-11 Merck & Co Inc CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ANDROGENIC RECEPTORS
EP2957568B1 (en) 2002-11-05 2016-12-21 Ionis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
AU2003291753B2 (en) 2002-11-05 2010-07-08 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
EP2213738B1 (en) 2002-11-14 2012-10-10 Dharmacon, Inc. siRNA molecules targeting Bcl-2
US6673661B1 (en) 2002-12-20 2004-01-06 Taiwan Semiconductor Manufacturing Co., Ltd. Self-aligned method for forming dual gate thin film transistor (TFT) device
AU2004204068B8 (en) 2003-01-03 2010-03-25 Gencia Corporation SiRNA Mediated Post - Transcriptional Gene Silencing of Genes involved in Alopecia
BRPI0406778A (pt) 2003-01-17 2006-01-17 Warner Lambert Co Antagonistas de receptores de androgênio
JP2004254600A (ja) 2003-02-26 2004-09-16 Sumitomo Chem Co Ltd 変異型アンドロゲンレセプターおよびその活性評価用細胞
JP2004254601A (ja) 2003-02-26 2004-09-16 Sumitomo Chem Co Ltd 変異型アンドロゲンレセプターおよびその活性評価用細胞
DE10322108B4 (de) 2003-05-09 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Antiandrogene Pyrrolidine mit tumorhemmender Wirksamkeit
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
ATE555118T1 (de) 2003-08-28 2012-05-15 Takeshi Imanishi Neue synthetische nukleidsäuren vom typ mit quervernetzter n-o-bindung
JP5379347B2 (ja) 2003-09-18 2013-12-25 アイシス ファーマシューティカルズ， インコーポレーテッド ４’−チオヌクレオシドおよびオリゴマー化合物
US20050164970A1 (en) 2003-12-22 2005-07-28 University Of Kansas Medical Center Method for treating prostate cancer using siRNA duplex for androgen receptor
US20050244851A1 (en) 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
EP1716164A1 (en) 2004-02-20 2006-11-02 Genesis Research and Development Corporation Limited Targeted delivery of rna interference molecules for the treatment of ige-mediated disorders
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
CA2566286A1 (en) 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
WO2005115361A2 (en) 2004-05-17 2005-12-08 Acadia Pharmaceuticals Inc. Androgen receptor modulators and method of treating disease using the same
DE102004025881A1 (de) 2004-05-19 2006-01-05 Beiersdorf Ag Oligoribonukleotide zur Beeinflussung des Haarwachstums
CA2569419A1 (en) 2004-06-03 2005-12-22 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
WO2006020768A2 (en) 2004-08-10 2006-02-23 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides
WO2006047842A2 (en) 2004-11-08 2006-05-11 K.U. Leuven Research And Development Modified nucleosides for rna interference
US20070248535A1 (en) 2005-02-07 2007-10-25 The Trustees Of Columbia University In The City Of New York Methods to treat or prevent hormone-resistant prostate cancer using siRNA specific for protocadherin-PC, or other inhibitors of protocadherin-PC expression or activity
US8912317B2 (en) 2005-02-11 2014-12-16 International Business Machines Corporation Ribonucleic acid interference molecules of Arabidopsis thaliana
US8795987B2 (en) 2005-02-11 2014-08-05 International Business Machines Corporation Ribonucleic acid interference molecules of Oryza sativa
US20070154896A1 (en) 2005-02-11 2007-07-05 International Business Machines Corporation System and method for identification of MicroRNA target sites and corresponding targeting MicroRNA sequences
US20070213293A1 (en) 2005-04-08 2007-09-13 Nastech Pharmaceutical Company Inc. Rnai therapeutic for respiratory virus infection
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
WO2007014370A2 (en) 2005-07-28 2007-02-01 University Of Delaware Small regulatory rnas and methods of use
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
EP1984381B1 (en) 2006-01-27 2010-09-29 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
JP4961549B2 (ja) 2006-02-16 2012-06-27 国立大学法人愛媛大学 アンドロゲン受容体遺伝子に特異的なｓｉＲＮＡ
US8178503B2 (en) 2006-03-03 2012-05-15 International Business Machines Corporation Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes
LT2656841T (lt) 2006-03-27 2016-09-26 The Regents Of The University Of California Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui
JP2007282598A (ja) 2006-04-19 2007-11-01 Japan Health Science Foundation 性分化異常症診断マーカー
ES2389737T3 (es) 2006-05-11 2012-10-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos modificados en 5'
JP4798093B2 (ja) 2006-08-04 2011-10-19 日産自動車株式会社 流体改質装置及びこれを用いた流体改質方法
AR055648A1 (es) 2006-09-21 2007-08-29 Gen Med Sa Un oligonucleotido de rna de doble cadena una composicion farmaceutica o cosmetica que lo comprende y uso del mismo enla preparacion de un medicamento para el tratamiento de enfermedades relacionadas con el metabolismo de androgenos
EP2140027B1 (en) 2006-12-07 2012-07-18 Novartis AG Non-invasive prenatal genetic screen
US7960435B2 (en) 2006-12-15 2011-06-14 University Of Maryland, Baltimore Anti-cancer agents and androgen inhibition activity compound
EP2125852B1 (en) 2007-02-15 2016-04-06 Ionis Pharmaceuticals, Inc. 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
WO2008119015A2 (en) 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
US8278425B2 (en) 2007-05-30 2012-10-02 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
DK2173760T4 (en) 2007-06-08 2016-02-08 Isis Pharmaceuticals Inc Carbocyclic bicyclic nukleinsyreanaloge
US8278283B2 (en) 2007-07-05 2012-10-02 Isis Pharmaceuticals, Inc. 6-disubstituted or unsaturated bicyclic nucleic acid analogs
US8486904B2 (en) * 2007-10-01 2013-07-16 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
US8546556B2 (en) 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs
US8450290B2 (en) 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
EP2225377B1 (en) 2007-11-26 2014-01-08 Santaris Pharma A/S Lna antagonists targeting the androgen receptor
PE20091157A1 (es) 2007-12-21 2009-09-03 Astrazeneca Ab Derivados biciclicos para usar en el tratamiento de afecciones asociadas con el receptor de androgeno - 155
EP2265627A2 (en) 2008-02-07 2010-12-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
WO2009102446A2 (en) 2008-02-12 2009-08-20 The Brigham And Women's Hospital, Inc. Fish assay for eml4 and alk fusion in lung cancer
FR2929292A1 (fr) 2008-03-28 2009-10-02 Exonhit Therapeutics S A Sa Procede et methodes de diagnostic de la maladie d'alzheimer
US20090282496A1 (en) 2008-04-04 2009-11-12 University Of Rochester Medical Center Androgen Receptor Related Methods for Treating Bladder Cancer
ES2566750T3 (es) 2008-04-16 2016-04-15 The Johns Hopkins University Método para determinar el riesgo de recidiva de cáncer de próstata
MX2011002143A (es) 2008-08-25 2011-07-20 Excaliard Pharmaceuticals Inc Oligonucleotidos antisentido dirigidos contra el factor de crecimiento del tejido conectivo y usos de los mismos.
US8133724B2 (en) 2008-09-17 2012-03-13 University Of Maryland, Baltimore Human androgen receptor alternative splice variants as biomarkers and therapeutic targets
EP2361256B1 (en) 2008-09-24 2013-04-10 Isis Pharmaceuticals, Inc. Cyclohexenyl nucleic acid analogs
WO2010036698A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
WO2010062914A1 (en) 2008-11-26 2010-06-03 The Johns Hopkins University Methods for identifying cancer risk
JP2010148501A (ja) 2008-11-28 2010-07-08 Hisamitsu Pharmaceut Co Inc がんマーカー、及び、がんの治療剤
US20140004565A1 (en) 2009-07-06 2014-01-02 Alnylam Pharmaceuticals, Inc. Cell-based bioprocessing
CA2767207A1 (en) 2009-07-06 2011-01-13 Alnylam Pharmaceuticals, Inc. Bioprocessing
AU2011218173C1 (en) 2010-02-16 2015-04-16 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
WO2011112581A1 (en) 2010-03-08 2011-09-15 Regents Of The University Of Minnesota Androgen receptor isoforms and methods
EP2545173A2 (en) 2010-03-12 2013-01-16 Sarepta Therapeutics, Inc. Antisense modulation of nuclear hormone receptors
JP6005628B2 (ja) 2010-04-28 2016-10-12 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 修飾ヌクレオシド、その類似体、およびこれらから調製されるオリゴマー化合物
NZ603606A (en) 2010-05-28 2015-06-26 Sarepta Therapeutics Inc Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
WO2012005898A2 (en) 2010-06-15 2012-01-12 Alnylam Pharmaceuticals, Inc. Chinese hamster ovary (cho) cell transcriptome, corresponding sirnas and uses thereof
CA2804210A1 (en) * 2010-07-06 2012-01-12 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of androgen receptor by double-stranded rna
AU2011282217B2 (en) * 2010-07-19 2015-12-03 Ionis Pharmaceuticals, Inc. Modulation of dystrophia myotonica-protein kinase (DMPK) expression
WO2012018881A2 (en) 2010-08-03 2012-02-09 Alnylam Pharmaceuticals, Inc. Methods and compositions for the regulation of rna
AU2011326034B2 (en) 2010-11-12 2016-02-04 Roche Innovation Center Copenhagen A/S Compositions and methods for treating androgen receptor dependent disorders including cancers
WO2012087983A1 (en) 2010-12-20 2012-06-28 The General Hospital Corporation Polycomb-associated non-coding rnas
PT2670411T (pt) 2011-02-02 2019-06-18 Excaliard Pharmaceuticals Inc Compostos anti sentido visando um fator de crescimento do tecido conetivo (ctfg) para utilização num método de tratamento de queloides ou cicatrizes hipertróficas
WO2012109395A1 (en) 2011-02-08 2012-08-16 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
WO2012120374A2 (en) * 2011-03-10 2012-09-13 Oslo Universitetssykehus Hf Methods and biomarkers for detection of gastrointestinal cancers
EP2751270B1 (en) 2011-08-29 2018-08-22 Ionis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
US20140378533A1 (en) 2012-02-08 2014-12-25 Isis Pharmaceuticals, Inc. Modulation of rna by repeat targeting
US9778706B2 (en) 2012-02-24 2017-10-03 Blackberry Limited Peekable user interface on a portable electronic device
US9984408B1 (en) 2012-05-30 2018-05-29 Amazon Technologies, Inc. Method, medium, and system for live video cooperative shopping
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression

Also Published As

Publication number Publication date
PL2906226T3 (pl) 2019-04-30
CA2887867A1 (en) 2014-04-17
USRE48461E1 (en) 2021-03-09
RU2670486C9 (ru) 2019-04-01
CN104703610A (zh) 2015-06-10
AU2013329070A1 (en) 2015-04-16
TW201420594A (zh) 2014-06-01
CN108300718A (zh) 2018-07-20
ZA201503203B (en) 2016-09-28
US9567588B2 (en) 2017-02-14
RU2670486C2 (ru) 2018-10-23
IL262218A (en) 2018-11-29
MX369207B (es) 2019-10-31
JP6599497B2 (ja) 2019-10-30
MX2015004641A (es) 2015-07-14
US20140107180A1 (en) 2014-04-17
US20160068846A1 (en) 2016-03-10
CA2887867C (en) 2019-09-24
KR102124228B1 (ko) 2020-06-17
CL2015000901A1 (es) 2016-02-26
EP2906226A2 (en) 2015-08-19
DOP2015000083A (es) 2015-06-15
EP2906226B1 (en) 2018-11-21
RU2015111672A (ru) 2016-12-10
WO2014059238A2 (en) 2014-04-17
DK2906226T3 (en) 2019-02-18
AU2017200759A1 (en) 2017-03-02
SG11201502505UA (en) 2015-04-29
CO7400882A2 (es) 2015-09-30
WO2014059238A8 (en) 2015-04-16
JP2018126141A (ja) 2018-08-16
WO2014059238A3 (en) 2014-06-19
AU2017200759B2 (en) 2018-07-19
TN2015000140A1 (en) 2016-10-03
KR20150064210A (ko) 2015-06-10
AP2015008368A0 (en) 2015-04-30
IL262218B (en) 2020-08-31
PH12015500788A1 (en) 2015-06-15
CN104703610B (zh) 2018-03-23
AR092982A1 (es) 2015-05-13
NZ706151A (en) 2018-11-30
NI201500051A (es) 2016-02-15
US9175291B2 (en) 2015-11-03
HK1258404A1 (zh) 2019-11-08
JP2016501513A (ja) 2016-01-21
ES2706387T3 (es) 2019-03-28
HK1213774A1 (en) 2016-07-15
JP6306598B2 (ja) 2018-04-04
PE20150722A1 (es) 2015-06-03
ECSP15012462A (es) 2015-12-31
BR112015007878A2 (pt) 2017-11-28
IL237855A0 (en) 2015-05-31
PT2906226T (pt) 2019-02-25
EP2906226A4 (en) 2016-06-08
CN108300718B (zh) 2022-02-22

Similar Documents

Publication Publication Date Title
DOP2015000083A (es) Modulación de la expresión de receptores androgénicos
PH12014500248B1 (en) Treatment of breast cancer
CL2017003456A1 (es) Metodos para tratar tumores de celulas epitelioides
PH12019502379A1 (en) Pd-1/pd-l1 inhibitors
EA201390756A1 (ru) Модулирующие nk-клетки терапии и способы для лечения гематологических злокачественных заболеваний
MX358514B (es) Compuestos para tratar la atrofia muscular espinal.
CL2018000429A1 (es) Moduladores de la expresión de kras
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
DOP2015000227A (es) Virus de la enfermedad de newcastle y usos de los mismos
EA201590987A1 (ru) Соединения и способы их применения
MX2015013686A (es) Composiciones y metodos para potenciar la estabilidad microbiana.
UY35812A (es) ?loci de maíz óptimos?.
DK3281607T3 (da) Implanterbar protese med acellulære vævsvedhæftninger.
MX359769B (es) Metodos para descelularizar huesos.
CL2015000715A1 (es) Anti-androgenos para el tratamiento de cáncer prostatico no metastasico y resistente de castracion
MX2015013177A (es) Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki.
MX360774B (es) Antagonistas de progesterona.
DK3460052T3 (da) Forbedrede allogene dendrittiske celler til anvendelse i behandling af cancer
IN2014KN02620A (es)
IN2014DN09408A (es)
MX2021008225A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
MY181685A (en) Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer
MX2015013021A (es) 5-bromo-indirrubinas.
CL2016002532A1 (es) Compuestos derivados de diheterociclo enlazado a cicloalquilo con actividad inhibidora de gls1 uso en el tratamiento de crecimiento celular anormal, tal como cáncer composición farmacéutica que los contiene

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210617